IBBR Seminar Series

Structural Biology’s Role in Developing Antibody Therapeutics

Summary:  Antibodies make up the largest, growing segment of protein therapeutics in the pharmaceutical and biotechnology industries. The development or engineering of therapeutic antibodies is based on our knowledge of antibody structure and requires sophisticated methods that continue to evolve. These methods include antibody humanization, antigen-affinity optimization, Fc engineering for modulating effector function and extending half-life, and engineering for improved stability and biophysical properties.